More recently, promising but preliminary results were reported for the CCR1 inhibitor CCX354-C in RA patients as well as the CCR9 inhibitor CCX282 in Crohn’s disease and inflammatory bowel disease [60]. Here, CCR1 is linked to inflammatory bowel disease.